BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Argus Health
Johnson and Johnson
Julphar
Daiichi Sankyo
Federal Trade Commission
Fish and Richardson
Cantor Fitzgerald
McKinsey
Mallinckrodt

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 206829

« Back to Dashboard

NDA 206829 describes ZERBAXA, which is a drug marketed by Cubist Pharms Llc and is included in one NDA. It is available from one supplier. There are six patents protecting this drug. Additional details are available on the ZERBAXA profile page.

The generic ingredient in ZERBAXA is ceftolozane sulfate; tazobactam sodium. One supplier is listed for this compound. Additional details are available on the ceftolozane sulfate; tazobactam sodium profile page.
Summary for 206829
Tradename:ZERBAXA
Applicant:Cubist Pharms Llc
Ingredient:ceftolozane sulfate; tazobactam sodium
Patents:6
Formulation / Manufacturing:see details
Pharmacology for NDA: 206829
Ingredient-typeCephalosporins
Mechanism of Actionbeta Lactamase Inhibitors
Suppliers and Packaging for NDA: 206829
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ZERBAXA ceftolozane sulfate; tazobactam sodium POWDER;IV (INFUSION) 206829 NDA Merck Sharp & Dohme Corp. 67919-030 67919-030-01 10 VIAL, SINGLE-DOSE in 1 CARTON (67919-030-01) > 10 mL in 1 VIAL, SINGLE-DOSE

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:POWDER;IV (INFUSION)StrengthEQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL
Approval Date:Dec 19, 2014TE:RLD:Yes
Regulatory Exclusivity Expiration:Dec 19, 2024
Regulatory Exclusivity Use:GENERATING ANTIBIOTIC INCENTIVES NOW
Regulatory Exclusivity Expiration:Dec 19, 2019
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:➤ SubscribePatent Expiration:Oct 21, 2024Product Flag?YSubstance Flag?YDelist Request?
Patented Use:METHODS OF TREATING BACTERIAL ILLNESSES

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Covington
Farmers Insurance
Deloitte
Novartis
Mallinckrodt
Daiichi Sankyo
Express Scripts
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot